ChromaDex Co. (NASDAQ:CDXC) CFO Buys $21,395.52 in Stock

ChromaDex Co. (NASDAQ:CDXC) CFO Ozan Pamir bought 2,907 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were acquired at an average price of $7.36 per share, with a total value of $21,395.52. Following the purchase, the chief financial officer now owns 2,907 shares of the company’s stock, valued at $21,395.52. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

ChromaDex Stock Up 0.4 %

Shares of CDXC traded up $0.03 during mid-day trading on Monday, reaching $7.47. 272,374 shares of the stock traded hands, compared to its average volume of 539,281. ChromaDex Co. has a 12-month low of $1.32 and a 12-month high of $7.85. The firm has a market cap of $570.56 million, a price-to-earnings ratio of 744.74 and a beta of 1.88. The stock has a fifty day simple moving average of $4.61 and a 200 day simple moving average of $3.59.

ChromaDex (NASDAQ:CDXC) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The business had revenue of $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. During the same period last year, the firm earned ($0.01) earnings per share. On average, equities research analysts expect that ChromaDex Co. will post 0.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. StockNews.com downgraded shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 18th. Roth Mkm increased their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, HC Wainwright lifted their price objective on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 4th.

Institutional Trading of ChromaDex

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its holdings in shares of ChromaDex by 1.6% during the third quarter. Geode Capital Management LLC now owns 1,149,592 shares of the company’s stock valued at $4,197,000 after acquiring an additional 17,963 shares during the period. State Street Corp lifted its stake in shares of ChromaDex by 11.3% in the 3rd quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after purchasing an additional 62,692 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of ChromaDex by 8.4% in the 2nd quarter. Renaissance Technologies LLC now owns 416,100 shares of the company’s stock valued at $1,136,000 after acquiring an additional 32,400 shares in the last quarter. WINTON GROUP Ltd acquired a new stake in shares of ChromaDex in the second quarter worth $597,000. Finally, Bank of New York Mellon Corp grew its position in shares of ChromaDex by 170.0% in the second quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after purchasing an additional 119,915 shares during the last quarter. 15.41% of the stock is owned by institutional investors and hedge funds.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.